Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05063162 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
A Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT05063162: Active Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), sponsored by UCB Biopharma SRL.
NCT05063162 is a Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 104 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05063162, a Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Primary Outcome
The TTFR (days) will be defined as the interval between the date of randomization and the first date of the objective relapse. During the Double Blind (DB) Treatment Period (Part A); EDB/EWD = End of Double-Blind/Early Withdrawal Visit
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rozanolixizumab
Study Locations (20)
Other
- Mog001 30022 - Melbourne
- Mog001 40123 - Anderlecht
- Mog001 40756 - Bruxelles/brussel
- Mog001 40122 - Edegem
- Mog001 40185 - Ghent
- Mog001 60033 - Porto Alegre
Texas
- Mog001 50304 - Dallas
- Mog001 50568 - San Antonio
Arizona
- Mog001 50297 - Scottsdale
California
- Mog001 50450 - Palo Alto
Colorado
- Mog001 50101 - Aurora
District of Columbia
- Mog001 50553 - Washington D.C.
Florida
- Mog001 50308 - Tampa
Illinois
- Mog001 50472 - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 3 |
What the registry record for NCT05063162 still lists
NCT05063162 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05063162 names 20 study sites across 14 states, led by Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05063162 about?
NCT05063162 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)". The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
What is the current status of trial NCT05063162?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2022-02-02. Estimated completion is 2027-07-01.
What conditions does trial NCT05063162 study?
This clinical trial studies the following conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
What interventions are being tested in trial NCT05063162?
The interventions under investigation include: Placebo (OTHER), Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT05063162?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05063162 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05063162's enrollment target sits among peer trials
104 1671st of 2000 higher than 327 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI